You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The companies intend to study de-identified, population-scale phenotypic and genotypic data to gain unique insights that may support the broader HCM ecosystem.
The partnership will allow people to see their genetic risk with other health data that Seqster pulls from electronic health records and wearables.
The phenome-wide association study focused on SNPs near potential drug target sites with ties to one or more phenotypes that might impact target suitability.
Fortune discusses consumer genetic testing companies' privacy policies.
23andMe has stopped allowing third-party apps access to anonymized genomic data, according to Wired.
CNBC reports that genetic testing company 23andMe is looking into offering a premium sequencing-based service.
ADx Healthcare is selling an APOE test on the Helix marketplace, while HealthLytix and Dash Genomics are marketing a polygenic hazard score for late-onset Alzheimer's.
Using data for more than 500,000 individuals, researchers found 15 fracture-linked loci and saw genetic interactions between fracture and bone mineral density.
23andMe is evaluating how third-party services are impacting customers' experiences and would like to see those services be more complementary to its own efforts.
23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.
A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.
Nature News writes that viral genomic surveillance in the US faces systemic issues.
President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.
In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.